Blood Collection in Strong Acidic Citrate Anticoagulant Used in a Study of Dietary Influence on Basal tPA Activity

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Thrombosis and Haemostasis

• Publication date

  1989-11-24

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1055/s-0038-1651028PMID 2512680
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunoreactivity of Tissue Plasminogen Activator and of Its Inhibitor Complexes

  1989cited by this paper
• Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay.

  1988cited by this paper
• Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects.

  1986cited by this paper
• Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay.

  1986cited by this paper
• Release of vascular plasminogen activator (v‐PA) after venous stasis: electrophoretic—zymographic analysis of free and complexed v‐PA

  1985cited by this paper
• The role of the fibrinolytic system in deep vein thrombosis.

  1985cited by this paper
• Evidence for a rapid inhibitor to tissue plasminogen activator in plasma.

  1983cited by this paper
• An Enzyme Linked Immunosorbent Assay for Determination of Tissue Plasminogen Activator Applied to Patients with Thromboembolic Disease

  1983cited by this paper
• Plasminogen activator release during venous stasis and exercise as determined by a new specific assay.

  1983cited by this paper
• A sensitive assay for tissue plasminogen activator.

  1982cited by this paper
• Studies on the Fibrinolytic System in Human Plasma: Quantitative Determination of Plasminogen Activators and Proactivators

  1979cited by this paper
• Defective fibrinolysis in blood and vein walls in recurrent "idiopathic" venous thrombosis.

  1972cited by this paper
• Observations on fibrinolysis; experimental activity produced by exercise or adrenaline.

  1947cited by this paper

• Assays to quantify fibrinolysis: strengths and limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on fibrinolysis.

  2023cites this paper
• Hyperfibrinolysis

  2021cites this paper
• Lysis Timer: a new sensitive tool to diagnose hyperfibrinolysis in liver transplantation

  2018cites this paper
• Plasminogen Activator Inhibitor-1 Is a Marker and a Mediator of Senescence.

  2017cites this paper
• Approach for Half-Life Extension of Small Antibody Fragments That Does Not Affect Tissue Uptake.

  2016cites this paper
• Fibrinolysis in patients with a mild-to-moderate bleeding tendency of unknown cause

  2016cites this paper
• Self-Reported Sitting Time, Physical Activity and Fibrinolytic and Other Novel Cardio-Metabolic Biomarkers in Active Swedish Seniors

  2016cites this paper
• Shedded cell membrane proteins in plasma: Pure waste, or informative biomarkers of pathophysiological processes?

  2015cites this paper
• Half-life extension of the HIV-fusion inhibitor peptide TRI-1144 using a novel linker technology.

  2015cites this paper
• Stroke in Young Adults in Northern Sweden

  2014cites this paper
• Fibrinolytic factors in relation to anthropometry and incident type 2 diabetes.

  2014cites this paper
• Macromolecular prodrug that provides the irinotecan (CPT-11) active-metabolite SN-38 with ultralong half-life, low C(max), and low glucuronide formation.

  2014cites this paper
• oscillation of plasma PAI-1 The 4G5G polymorphism in the gene for PAI-1 and the circadian

  2013cites this paper
• Diagnosis of Fibrinolytic Disorders

  2012cites this paper
• Global haemostasis assays, from bench to bedside.

  2012cites this paper
• Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure--a COMET substudy.

  2010cites this paper
• Beyond the established risk factors of myocardial infarction : lifestyle factors and novel biomarkers

  2009cites this paper
• Peritoneal and systemic pH during pneumoperitoneum with CO2 and helium in a pig model

  2008cites this paper
• The influence of acute-phase levels of haemostatic factors on reperfusion and mortality in patients with acute myocardial infarction treated with streptokinase

  2008cites this paper
• BLOOD PRESSURE ELEVATION: IMPACT ON CARDIOVASCULAR STRUCTURE AND ENDOGENOUS FIBRINOLYSIS

  2008cites this paper
• Development of a new test for the global fibrinolytic capacity in whole blood

  2007cites this paper
• Strategies to reduce hemostatic activation during cardiopulmonary bypass.

  2006cites this paper
• ST-elevation myocardial infarction : studies of outcome in relation to fibrinolysis and ischemia monitoring with on-line vectorcardiography.

  2006cites this paper
• Endogenous t-PA release and pharmacological thrombolysis - Experimental animal studies of the coronary circulation

  2006influential citation
• The kinetics of plasmin inhibition by aprotinin in vivo.

  2005cites this paper
• Homocysteine in cardiovascular disease with special reference to longitudinal changes

  2005cites this paper
• Comparison of soluble thrombomodulin, von Willebrand factor, tPA/PAI-1 complex, and high-sensitivity CRP concentrations in serum, EDTA plasma, citrated plasma, and acidified citrated plasma (Stabilyte) stored at -70 degrees C for 8-11 years.

  2005cites this paper
• Key References: Basic Fibrinolysis and Thrombolysis Selected References: 1987–1997

  2004cites this paper
• A rapid microtitre plate screening method for in vitro assessment of fibrinolysis: a preliminary report

  2004cites this paper
• Effect of delapril–manidipine combination vs irbesartan–hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus

  2004cites this paper
• A comparison of the effects of cheese and butter on serum lipids, haemostatic variables and homocysteine

  2004cites this paper
• Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction

  2004cites this paper
• Zymographic evaluation of plasminogen activators and plasminogen activator inhibitors.

  2004cites this paper
• Analysis of cystatin C, creatinine, albumin, lipids and lipoprotein concentrations in serum and acidified citrate plasma (Stabilyte™) tubes compared

  2004cites this paper
• Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients

  2003cites this paper
• The 4G5G polymorphism in the gene for PAI-1 and the circadian oscillation of plasma PAI-1.

  2003cites this paper
• The Journal of Rheumatology Procoagulants and osteonecrosis.

  2003cites this paper
• Procoagulants and osteonecrosis.

  2003cites this paper
• A diet rich in coconut oil reduces diurnal postprandial variations in circulating tissue plasminogen activator antigen and fasting lipoprotein (a) compared with a diet rich in unsaturated fat in women.

  2003cites this paper
• Failure of peripheral arterial thrombolysis due to elevated plasminogen activator inhibitor type 1

  2003cites this paper
• Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin

  2003cites this paper
• Secretion of tissue plasminogen activator and plasminogen activator inhibitor 1 during cardiopulmonary bypass.

  2003cites this paper
• Influence of the Alu-Repeat I/D Polymorphism in t-PA Gene Intron 8 on the Stimulated t-PA Release After Venous Occlusion

  2003cites this paper
• Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease.

  2002cites this paper
• The effect of streptokinase neutralizing antibodies on fibrinolytic activity and reperfusion following streptokinase treatment in acute myocardial infarction

  2002cites this paper
• Plasminogen Activator Inhibitor-1 and Vascular Disease in Diabetes Mellitus

  2001cites this paper
• Covariance of metabolic and hemostatic risk indicators in men and women

  2001cites this paper
• Factor XIIIA and clot strength after cardiopulmonary bypass

  2001cites this paper
• Partially hydrogenated soybean oil reduces postprandial t-PA activity compared with palm oil.

  2001cites this paper
• Arginine inhibits hemostasis activation.

  2001cites this paper
• Trombofilia y enfermedad de Perthes

  2000cites this paper
• Measurement of different forms of tissue plasminogen activator in plasma.

  2000cites this paper
• Plasminogen activation in multiple sclerosis and other neurological disorders

  2000cites this paper
• Formation, Inhibition and Clearance of Plasmin in vivo

  2000cites this paper
• Criteria and Search for Specific Assays for Active Plasminogen Activator Inhibitor 1 (PAI-1) in Plasma

  2000cites this paper
• Improved fibrinolytic capacity after withdrawal of steroid immunosuppression in renal transplant recipients.

  2000cites this paper
• Hyperhomocysteinemia and hypofibrinolysis in young adults with ischemic stroke.

  1999cites this paper
• Tissue-type plasminogen activator (t-PA) activity

  1999cites this paper
• Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation.

  1999cites this paper
• Blood sampling conditions in functional assays sensitive for pro-urokinase

  1999cites this paper
• Fibrinolytic properties of activated FXII.

  1999cites this paper
• Depression of peritoneal fibrinolysis during operation is a local response to trauma.

  1998cites this paper
• Postprandial effects of an oleic acid-rich oil compared with butter on clotting factor VII and fibrinolysis in healthy men.

  1998cites this paper
• Effect on plasma lipids and lipoproteins of replacing partially hydrogenated fish oil with vegetable fat in margarine

  1998cites this paper
• Exogenous estrogen may exacerbate thrombophilia, impair bone healing and contribute to development of chronic facial pain.

  1998cites this paper
• Elevated plasma fibrinogen: cause or consequence of cardiovascular disease?

  1998cites this paper
• Heparin-coated bypass circuits (Carmeda) suppress the release of tissue plasminogen activator during normothermic coronary artery bypass graft surgery.

  1998cites this paper
• Tissue markers as predictors of postoperative adhesions

  1998cites this paper
• Sex Differences in the Determinants of Fibrinolytic Activity

  1998cites this paper
• Increased fibrinogen levels and acquired hypofibrinolysis in young adults with ischemic stroke.

  1998cites this paper
• Expression and kinetics of fibrinolytic components in plasma and peritoneum during abdominal surgery

  1998cites this paper
• Intense nonpharmacological intervention in subjects with multiple cardiovascular risk factors: decreased fasting insulin levels but only a minor effect on plasma plasminogen activator inhibitor activity.

  1998cites this paper
• Effects of doxazosin and atenolol on atherothrombogenic risk profile in hypertensive middle-aged men.

  1998cites this paper
• Impairment of fibrinolytic potential in long-term steroid treatment after heart transplantation.

  1997cites this paper
• Relationship between Fibrinolytic Activity following Streptokinase Treatment in Acute Myocardial Infarction and Vectorcardiographic signs of Reperfusion

  1997cites this paper
• Contribution of platelets to PAI-1 concentration in plasma of patients with primary and secondary thrombocytosis

  1997cites this paper
• Plasma and cerebrospinal fluid activities of tissue plasminogen activator, urokinase and plasminogen activator inhibitor-1 in multiple sclerosis

  1997cites this paper
• A Comparison of Thromboelastography with Heparinase or Protamine Sulfate Added In Vitro during Heparinized Cardiopulmonary Bypass

  1997cites this paper
• Thrombolysis, With or Without Heparin, During the First Nine Weeks After Acute Myocardiat Infarction

  1997cites this paper
• Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels.

  1997cites this paper
• Cerebrospinal fluid plasminogen activator inhibitor-1 in patients with neurological disease.

  1997cites this paper
• Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam Study.

  1997cites this paper
• Two variants of extracellular‐superoxide dismutase: relationship to cardiovascular risk factors in an unselected middle‐aged population

  1997cites this paper
• The effect of chemical anti-inhibitors on fibrinolytic enzymes and inhibitors.

  1997cites this paper
• Gemfibrozil treatment of hypertriglyceridemia: improvement on fibrinolysis without change of insulin resistance.

  1997cites this paper
• Thrombophilia and hypofibrinolysis: pathophysiologies of osteonecrosis.

  1997cites this paper
• The Difference of Thrombogenic and Fibrinolytic Factors inPremenopausal and Menopausal Women

  1997cites this paper
• XR5118, a novel modulator of plasminogen activator inhibitor-1 (PAI-1), increases endogenous tPA activity in the rat

  1997cites this paper
• Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM

  1997cites this paper
• An Experimental Multiple-Organ Model for the Study of Regional Net Release/Uptake Rates of Tissue-type Plasminogen Activator in the Intact Pig

  1997cites this paper
• Haemostasis and cardiovascular disease

  1997cites this paper
• Chromolize™ PAI-1: a new assay for active plasminogen activator inhibitor type 1 adapted for use with Stabilyte™ vials

  1996cites this paper
• Insulin resistance syndrome and fibrinolytic activity: the northern Sweden MONICA study.

  1996cites this paper
• The use of Stabilyte® plasma may cause changes in pH in the assay of some fibrinolysis analytes and might effect results*

  1996cites this paper
• 12. Circadian fluctuation of fibrinolytic factors in blood Investigation, importance and clinical consequences

  1996cites this paper
• Magnesium therapy, fibrinolytic parameters and von Willebrand factor in acute myocardial infarction.

  1996cites this paper
• Update 1996: Blood collection and handling procedures for assessment of plasminogen activators and inhibitors (Leiden Fibrinolysis Workshop)

  1996cites this paper
• Pharmacokinetics of human recombinant tissue-type plasminogen activator, administered intra-abdominally, in a rat peritonitis model.

  1996cites this paper
• Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension.

  1996cites this paper
• Effect of doxazosin on fibrinolysis in hypertensive patients with and without insulin resistance.

  1996cites this paper